Innoveren Scientific Management
Management criteria checks 3/4
Innoveren Scientific's CEO is Michael Yurkowsky, appointed in Dec 2021, has a tenure of 2.42 years. total yearly compensation is $507.79K, comprised of 35.4% salary and 64.6% bonuses, including company stock and options. directly owns 0.18% of the company’s shares, worth $192.06. The average tenure of the management team and the board of directors is 2.4 years and 5.3 years respectively.
Key information
Michael Yurkowsky
Chief executive officer
US$507.8k
Total compensation
| CEO salary percentage | 35.4% |
| CEO tenure | 2.4yrs |
| CEO ownership | 0.2% |
| Management average tenure | 2.4yrs |
| Board average tenure | 5.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$3m |
| Jun 30 2023 | n/a | n/a | -US$5m |
| Mar 31 2023 | n/a | n/a | -US$8m |
| Dec 31 2022 | US$508k | US$180k | -US$10m |
| Sep 30 2022 | n/a | n/a | -US$10m |
| Jun 30 2022 | n/a | n/a | -US$8m |
| Mar 31 2022 | n/a | n/a | -US$7m |
| Dec 31 2021 | US$372k | US$15k | -US$5m |
| Sep 30 2021 | n/a | n/a | -US$6m |
| Jun 30 2021 | n/a | n/a | -US$1m |
| Mar 31 2021 | n/a | n/a | -US$6m |
| Dec 31 2020 | n/a | n/a | -US$7m |
| Sep 30 2020 | n/a | n/a | -US$26m |
| Jun 30 2020 | n/a | n/a | -US$33m |
| Mar 31 2020 | n/a | n/a | -US$32m |
| Dec 31 2019 | US$5k | n/a | -US$33m |
Compensation vs Market: Michael's total compensation ($USD507.79K) is about average for companies of similar size in the US market ($USD667.63K).
Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.
CEO
Michael Yurkowsky (51 yo)
2.4yrs
Tenure
US$507,787
Compensation
Mr. Michael W. Yurkowsky serves as Chief Executive Officer at Innoveren Scientific Inc. (formerly known as H-CYTE, Inc.) since December 6, 2021. He serves as Chairman of Deverra Therapeutics inc and serves...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.4yrs | US$507.79k | 0.18% $ 192.1 | |
| Chief Financial Officer | 5.3yrs | US$200.00k | 0.052% $ 55.0 | |
| Chief Scientific Officer | 2.3yrs | US$252.00k | 0.81% $ 864.8 | |
| Controller & Principal Accounting Officer | no data | no data | no data |
2.4yrs
Average Tenure
48.5yo
Average Age
Experienced Management: IVRN's management team is considered experienced (2.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.3yrs | US$507.79k | 0.18% $ 192.1 | |
| Independent Director | 2.3yrs | no data | no data | |
| Chairman of the Board | 5.3yrs | no data | 0.075% $ 80.0 | |
| Director | 5.6yrs | US$110.50k | 0.089% $ 94.5 | |
| Independent Director | 2.3yrs | no data | no data |
5.3yrs
Average Tenure
64yo
Average Age
Experienced Board: IVRN's board of directors are considered experienced (5.3 years average tenure).